Genmab — Januar 2023
-
En såkaldt kollektiv afklapsning hele vejen rundt
-
Jeg forstår så ikke helt, hvorfor C25 skal have så store klø i.f.t. resterende lande i Europa.
-
Sundhed faldt i US i går. Det fortsatte i DK i dag i C25, hvor sektoren med især Novo fylder meget. Læg hertil det aktiespecifikke fald i f.eks. Maersk og Netcompany.
-
Det er korrekt, @Helge. Og du hygger dig vel, lige idag, med dine grønne laks
-
Onsdagens aktier: Svag prognose kostede Netcompany dyrt https://www.proinvestor.com/investornyt/931480/onsdagens-aktier-svag-prognose-kostede-netcompany-dyrt
-
Godmorgen
-
Teprotumumab for the treatment of thyroid eye disease https://www.tandfonline.com/doi/abs/10.1080/14712598.2023.2172328?src=&journalCode=iebt20
-
Godt entry niveau for den langsigtede investor. 4-10 mdr. Kortsigt risiko at kursen kan falde ned til 2400. https://www.proinvestor.com/boards/107914/$/109852
-
-
The other culled project, JNJ-8902, focused specifically on prostate cancer, with a phase 1 study looking to enroll more than twice as many patients as the JNJ-6358 trial. Recruitment wrapped up in September, and few updates have been posted since, except a pushback of the expected completion date from January 2023 to the end of June 2023. The trial was similarly not recruiting out of the U.S. but did include trial sites in Canada in addition to Israel and Spain.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind